University of Texas at Dallas

About: University of Texas at Dallas is a education organization based out in Richardson, Texas, United States. It is known for research contribution in the topics: Population & Computer science. The organization has 14986 authors who have published 35589 publications receiving 1293714 citations. The organization is also known as: UT-Dallas & UT Dallas.

What Determines the Scope of the Firm Over Time? A Focus on Institutional Relatedness

Abstract: “What determines the scope of the firm?” is one of the most fundamental questions in strategic management. We argue that, in addition to product relatedness, a focus on institutional relatedness—defined as an organization's informal linkages with dominant institutions that confer resources and legitimacy—helps answer this question. We address this question both longitudinally (firms in developed and emerging economies over time) and cross-sectionally (developed versus emerging economies), thus contributing to an institution-based theory of corporate diversification.

Privacy preservation in wireless sensor networks: A state-of-the-art survey

Abstract: Much of the existing work on wireless sensor networks (WSNs) has focused on addressing the power and computational resource constraints of WSNs by the design of specific routing, MAC, and cross-layer protocols. Recently, there have been heightened privacy concerns over the data collected by and transmitted through WSNs. The wireless transmission required by a WSN, and the self-organizing nature of its architecture, makes privacy protection for WSNs an especially challenging problem. This paper provides a state-of-the-art survey of privacy-preserving techniques for WSNs. In particular, we review two main categories of privacy-preserving techniques for protecting two types of private information, data-oriented and context-oriented privacy, respectively. We also discuss a number of important open challenges for future research. Our hope is that this paper sheds some light on a fruitful direction of future research for privacy preservation in WSNs.

Comparative business failures of foreign-controlled firms in the united states

Abstract: We explore the comparative business failures of foreign-owned or controlled firms and domestically owned firms. Original data are collected regarding foreign-controlled firms in the U.S. that filed for bankruptcy protection, were involuntarily liquidated or ceased operations mainly due to poor financial performance during the 1978-1988 period. Our results show that foreign-controlled firms fail less often than domestically owned firms. The patterns of foreign-controlled business failures and the impacts of entry modes, ownership types, and national culture on the failures of foreign-controlled firms are also examined.

Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.

Abstract: Using immunoblotting techniques we studied the sera from small cell lung cancer and non-small cell lung cancer patients for antibodies directed against p53. We have also characterized the majority of these patients' tumors for p53 mutations. In the sera of 13% of the patients (4 of 40 small cell lung cancer and 2 of 6 non-small cell lung cancer) we found antibodies specific for the p53 tumor suppressor gene product. All of the antibody-positive patients tested had p53 missense mutations and expressed detectable p53 antigen in their tumor cell lines. No anti-p53 antibodies were detected in sera from patients whose tumor had p53 stop, splice/stop, splice, or frameshift mutations (n = 10). Thus, while we find that the ability of lung cancer patients to develop anti-p53 antibodies is correlated with the type of p53 mutation, many patients have tumors with missense p53 mutations and did not develop anti-p53 antibodies. The presence of p53 antibodies was not correlated to stage, prior treatment, sex, or survival. None of these lung cancer patient sera had measurable amounts of p53 antigen. By immunoblotting all six anti-p53 antisera we were able to detect a variety of mutant p53 proteins (including those from antibody-negative patients) and detected wild-type p53 protein. The development of anti-p53 antibodies represents an interesting model system for studying immune responses in cancer patients against mutant oncogene products.